Minomic International Ltd

About Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company that has developed an in vitro diagnostic test for the detection of prostate cancer called MiCheck®. In clinical studies, MiCheck® has demonstrated superior specificity compared with prostate-specific antigen (PSA), which is the current standard of care. Currently, approximately 50% of men with elevated PSA have no evidence of prostate cancer following transrectal biopsy. Of those men that have cancer diagnosed at biopsy, many have a non-aggressive form of prostate cancer which does not require treatment. MiCheck® has the potential to significantly reduce the number of unnecessary biopsies performed, providing more certainty about treatment options without the need for painful and invasive biopsies. A key element of Minomic's diagnostic test is the detection of a protein called Glypican-1 (GPC-1). By developing an antibody, Miltuximab®, to GPC-1 Minomic has initiated the development of a therapeutic in the potential treatment of prostate, pancreatic and bladder cancer. The Company has commenced a first-in-human study to evaluate the safety and tumor targeting of Miltuximab®. In preclinical studies, Miltuximab® accurately targeted prostate, pancreatic and bladder cancer cells, and was well-tolerated and highly specific in mouse models of prostate cancer.